Sotac Pharmaceuticals Ltd
Incorporated in 2015, Sotac Pharmaceuticals
Ltd manufactures and sells a wide range of pharmaceutical products[1]
- Market Cap ₹ 139 Cr.
- Current Price ₹ 126
- High / Low ₹ 203 / 88.0
- Stock P/E 17.3
- Book Value ₹ 48.2
- Dividend Yield 0.00 %
- ROCE 15.5 %
- ROE 16.3 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 2.60 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 96.9 to 128 days.
- Working capital days have increased from 98.1 days to 174 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
28.60 | 48.84 | 76.96 | 103.75 | 96.99 | |
26.73 | 47.38 | 69.65 | 95.20 | 83.36 | |
Operating Profit | 1.87 | 1.46 | 7.31 | 8.55 | 13.63 |
OPM % | 6.54% | 2.99% | 9.50% | 8.24% | 14.05% |
0.22 | 0.11 | 0.93 | 0.25 | 3.90 | |
Interest | 0.33 | 1.03 | 2.04 | 1.74 | 2.58 |
Depreciation | 1.40 | 2.59 | 2.28 | 3.10 | 3.84 |
Profit before tax | 0.36 | -2.05 | 3.92 | 3.96 | 11.11 |
Tax % | 75.00% | 15.12% | 41.84% | 9.85% | 16.65% |
0.09 | -2.37 | 2.29 | 3.58 | 8.03 | |
EPS in Rs | 0.39 | -10.30 | 3.58 | 3.87 | 7.27 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 28% |
3 Years: | % |
TTM: | -7% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 151% |
3 Years: | % |
TTM: | 121% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 4% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Equity Capital | 2.30 | 2.30 | 8.05 | 11.05 | 11.05 |
Reserves | 0.76 | 0.19 | 11.41 | 34.21 | 42.20 |
13.44 | 17.13 | 22.04 | 24.86 | 43.70 | |
13.89 | 15.08 | 32.14 | 35.20 | 27.38 | |
Total Liabilities | 30.39 | 34.70 | 73.64 | 105.32 | 124.33 |
15.99 | 16.56 | 25.92 | 35.51 | 48.69 | |
CWIP | 0.00 | 0.00 | 0.04 | 5.12 | 0.20 |
Investments | 0.16 | 0.30 | 0.00 | 2.10 | 3.78 |
14.24 | 17.84 | 47.68 | 62.59 | 71.66 | |
Total Assets | 30.39 | 34.70 | 73.64 | 105.32 | 124.33 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
0.06 | -0.31 | 8.14 | -16.12 | -4.33 | |
-11.75 | -3.23 | -11.67 | -19.68 | -13.62 | |
11.40 | 3.38 | 13.14 | 29.54 | 16.09 | |
Net Cash Flow | -0.29 | -0.16 | 9.61 | -6.26 | -1.85 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|
Debtor Days | 88.83 | 43.94 | 69.91 | 92.49 | 128.37 |
Inventory Days | 39.53 | 44.76 | 86.93 | 82.57 | 108.26 |
Days Payable | 194.09 | 120.65 | 161.82 | 132.46 | 101.20 |
Cash Conversion Cycle | -65.73 | -31.95 | -4.98 | 42.61 | 135.42 |
Working Capital Days | 14.29 | 14.95 | 28.08 | 92.28 | 173.98 |
ROCE % | -5.39% | 10.02% | 15.53% |
Documents
Announcements
-
Structural Digital Database
30 May 2025 - Submission of SDD compliance certificate for FY ended March 31, 2025 with remedial actions noted.
-
Outcome of Board Meeting-XBRL
28 May 2025 - Sotac Pharmaceuticals Limited has informed regarding Outcome of Board Meeting held on 28-May-2025 for Dividend
-
Dividend
28 May 2025 - Audited FY25 financials approved; final dividend Rs.0.10/share recommended; audit unmodified opinion.
-
Outcome of Board Meeting
28 May 2025 - Sotac Pharma reports FY25 audited results with Rs.1112L PBT, Rs.0.10 final dividend recommended.
-
Board Meeting Intimation
23 May 2025 - Sotac Pharmaceuticals Limited has informed about Board Meeting to be held on 28-May-2025 to consider and approve the Yearly Audited Financial results of the Company …
Business Overview:[1]
SPL specializes in manufacturing a broad range of pharmaceutical products across various therapeutic areas, including anti-diabetic, anti-psychotic, vitamins, minerals, iron supplements, anti-cold, anti-allergic, dermatological treatments, antacids, anti-ulcer (PPI), anti-emetics, cardiac, antihypertensives, analgesic, antipyretic, anti-inflammatory, antibacterial, antiviral, general antibiotics (β-lactams and non-β-lactams), antifungal, and cephalosporins.